Ledger.Open graph →
SEC Form D · filed April 30, 2021

Janux Therapeutics, Inc

Offering
$125.0M
Sold
$125.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
La Jolla, CA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (22)

Stefan Heller · La Jolla, CADirectorJake Simson, Ph.D · La Jolla, CADirectorPeter Thompson, M.D · La Jolla, CADirectorDavid Campbell, Ph.D · La Jolla, CAExec · DirectorTighe J. Reardon · La Jolla, CAExecJay Lichter, Ph.D · La Jolla, CADirectorMelissa Walters · Houston, TXDirectorTheodore Pritchett Iii · Houston, TXExec · DirectorSignalfire Opportunities GP, LLC Series 15 · SAN FRANCISCO, CAExecGenevieve Hedrick · SAN DIEGO, CADirectorMatthew Blanchard · SAN DIEGO, CADirectorStacey P. Kirkconnell · Grand Cayman, Cayman IslandsDirectorVickie L. Capps · Brookfield, WIDirectorSheila Gujrathi · San Diego, CADirectorWord D. Peake · New York, NYExecRichard W. Wiltshire · NEW YORK, NYDirectorArnon Dinur · New York, NYDirectorGigi Levy-Weisss · New York, NYDirectorMike Mcneil · San Francisco, CADirectorSytse Sijbrandij · San Francisco, CAExec · DirectorVickie L. Capps · Brookfield, WIDirectorSheila Gujrathi · La Jolla, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗